JP2023551535A - Ｔ細胞がんを治療するための方法および材料 - Google Patents

Ｔ細胞がんを治療するための方法および材料 Download PDF

Info

Publication number
JP2023551535A
JP2023551535A JP2023533230A JP2023533230A JP2023551535A JP 2023551535 A JP2023551535 A JP 2023551535A JP 2023533230 A JP2023533230 A JP 2023533230A JP 2023533230 A JP2023533230 A JP 2023533230A JP 2023551535 A JP2023551535 A JP 2023551535A
Authority
JP
Japan
Prior art keywords
polypeptide
seq
amino acid
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023533230A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551535A5 (https=
Inventor
サラ ディナポリ
ジャクリン ダグラス
エミリー ハン－チュン シュエ
マイケル エス． フアン
ケネス ダブリュ． キンズラー
マキシミリアン コニグ
ブライアン ジェイ． モグ
ニコラス パパドポウロス
アンドリュー エム． パードール
スマン ポール
アレクサンダー エイチ． パールマン
バート フォーゲルシュタイン
シビン チョウ
Original Assignee
ザ・ジョンズ・ホプキンス・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ジョンズ・ホプキンス・ユニバーシティー filed Critical ザ・ジョンズ・ホプキンス・ユニバーシティー
Publication of JP2023551535A publication Critical patent/JP2023551535A/ja
Publication of JP2023551535A5 publication Critical patent/JP2023551535A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023533230A 2020-12-01 2021-12-01 Ｔ細胞がんを治療するための方法および材料 Pending JP2023551535A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063119753P 2020-12-01 2020-12-01
US63/119,753 2020-12-01
PCT/US2021/061453 WO2022119955A1 (en) 2020-12-01 2021-12-01 Methods and materials for treating t cell cancers

Publications (2)

Publication Number Publication Date
JP2023551535A true JP2023551535A (ja) 2023-12-08
JP2023551535A5 JP2023551535A5 (https=) 2024-11-29

Family

ID=79021888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533230A Pending JP2023551535A (ja) 2020-12-01 2021-12-01 Ｔ細胞がんを治療するための方法および材料

Country Status (7)

Country Link
US (1) US20240002541A1 (https=)
EP (1) EP4255482A1 (https=)
JP (1) JP2023551535A (https=)
CN (1) CN116867519A (https=)
AU (1) AU2021392655A1 (https=)
CA (1) CA3203773A1 (https=)
WO (1) WO2022119955A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120076829A (zh) 2022-10-18 2025-05-30 明治制果药业株式会社 T细胞肿瘤的治疗剂
WO2024102980A1 (en) * 2022-11-11 2024-05-16 Pasithea Therapeutics Corp. Anti-alpha5 integrin antibodies and uses thereof
WO2025051339A1 (en) * 2023-09-05 2025-03-13 Tiber Biotech Srl SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR
WO2025247325A1 (en) * 2024-05-30 2025-12-04 Hanx Biopharmaceuticals, (Wuhan) Ltd. Antibody-drug conjugates targeting trbv12 and uses thereof
WO2026011103A1 (en) * 2024-07-03 2026-01-08 Yale University Tcr-vβeta specific therapeutic molecules and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09509307A (ja) * 1993-12-08 1997-09-22 ティー セル サイエンスィズ インコーポレイテッド ヒト化抗体及びそれらの使用
JP2018517712A (ja) * 2015-06-01 2018-07-05 メディジーン イミュノテラピーズ ゲーエムベーハー Ｔ細胞受容体特異的抗体
WO2020010250A2 (en) * 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020091635A2 (ru) * 2018-12-25 2020-05-07 Закрытое Акционерное Общество "Биокад" Гуманизированные антитела против участка бета цепи 9-го семейства trbv9 ткр человека, и способы их применения
JP2020520920A (ja) * 2017-05-16 2020-07-16 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｍａｎａボディおよび使用方法
WO2020172598A1 (en) * 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
WO2020172596A1 (en) * 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3192810A1 (en) * 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09509307A (ja) * 1993-12-08 1997-09-22 ティー セル サイエンスィズ インコーポレイテッド ヒト化抗体及びそれらの使用
JP2018517712A (ja) * 2015-06-01 2018-07-05 メディジーン イミュノテラピーズ ゲーエムベーハー Ｔ細胞受容体特異的抗体
JP2020520920A (ja) * 2017-05-16 2020-07-16 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｍａｎａボディおよび使用方法
WO2020010250A2 (en) * 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020091635A2 (ru) * 2018-12-25 2020-05-07 Закрытое Акционерное Общество "Биокад" Гуманизированные антитела против участка бета цепи 9-го семейства trbv9 ткр человека, и способы их применения
WO2020172598A1 (en) * 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
WO2020172596A1 (en) * 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LOUISE F. RISNES ET AL.: "Disease-driving CD4+ T cell clonotypes persist for decades in celiac disease", JOURNAL OF CLINICAL INVESTIGATION, vol. 128, no. 6, JPN6025044694, June 2018 (2018-06-01), pages 2642 - 2650, ISSN: 0005721306 *

Also Published As

Publication number Publication date
CA3203773A1 (en) 2022-06-09
WO2022119955A1 (en) 2022-06-09
CN116867519A (zh) 2023-10-10
AU2021392655A9 (en) 2024-05-02
AU2021392655A1 (en) 2023-06-22
EP4255482A1 (en) 2023-10-11
US20240002541A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
US11434293B2 (en) Anti TRBC1 antigen binding domains
JP7208010B2 (ja) 癌を標的とするキメラ抗原受容体
JP6765966B2 (ja) 抗ｃｄ１９キメラ抗原受容体を使用する癌の処置
JP2022062040A (ja) プロｍ２マクロファージ分子の阻害剤と組み合わせてキメラ抗原受容体を用いる癌の処置
JP2023551535A (ja) Ｔ細胞がんを治療するための方法および材料
US20180066059A1 (en) Anti-b7-h6 antibody, fusion proteins, and methods of using the same
JP2021512635A (ja) 腫瘍微小環境を標的とするキメラ抗原受容体
AU2020207962A1 (en) Methods and compositions to improve the safety and efficacy of cellular therapies
KR20210013160A (ko) 다중-특이적 결합 단백질 및 그에 대한 개선
TW201806619A (zh) 嵌合抗原受體及pd-1抑制劑之組合療法
CN110520524A (zh) 靶向肿瘤微环境的嵌合抗原受体t细胞
KR20210106437A (ko) 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
WO2016126608A1 (en) Car-expressing cells against multiple tumor antigens and uses thereof
KR20210030406A (ko) Cd137 항원-결합 부위를 포함하는 fc 결합 단편
JP2022527481A (ja) 生物活性が改変されたインターロイキン－２バリアント
CN112292140B (zh) 靶向cd37和cd19的嵌合抗原受体
KR20230027056A (ko) 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
AU2020244756A1 (en) Compositions and methods for TCR reprogramming using fusion proteins
EP4727972A1 (en) Treatment of trbc1-positive t cell malignancies
RU2791327C2 (ru) Антигенсвязывающие домены против trbc1
RU2815417C2 (ru) Лечение злокачественной опухоли с использованием химерного рецептора антигена против cd19
WO2023150260A2 (en) Compounds that target tem8, compositions, and methods
HK40128442A (zh) 嵌合抗原和t细胞受体及使用的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260317